Floatz logo

Sgr-1505

MALT Lymphoma

Schrödinger, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

35 Active assets in the MALT Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
City of Hope Medical Center
Phase 3BBB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BBB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
VINCRISTINE SULFATE
SWOG Cancer Research Network
Phase 2BB

View all 50 →

Same molecule, other indications

Sgr-1505 is also rated in:

Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderlyDormant
CC
Indicative ·
43 / 100
View asset →
diffuse large B-cell lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
primary effusion lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →